The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Researchers at San Diego State University and Michigan State University are shedding new light on how viruses meticulously ...

As aging progresses, the quality of DNA and proteins inside cells declines, which is known to be the cause of various ...

Using artificial intelligence, MIT researchers have come up with a new way to design nanoparticles that can more efficiently ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...